title: Experimental study of nano-hydroxyapatite/recombinant human bone morphogenetic protein-2 composite artificial bone.
abstract: OBJECTIVE
  To investigate the repairing ability of nano-hydroxyapatite/recombinant human bone morphogenetic protein-2 (Nano-HA/rhBMP-2) composite artificial bone for bone defect and to provide evidence for its application in clinical repair of bone defect.
  
  
  METHODS
  The animal model of bone defect was made on unilateral radius of 90 New Zealand white rabbits, which were randomly divided into experimental group (group A, bone defect was repaired with Nano-HA/rhBMP-2 composite artificial bone), control group (group B, bone defect was repaired with Nano-HA artificial bone), and blank group (group C, bone defect was unrepaired). The repairing ability for bone defect was evaluated by gross observation, X-ray examination, scanning electron microscope, radionuclide bone imaging and biomechanical analysis at 4(th), 8(th), and 12th week postoperatively.
  
  
  RESULTS
  Both Nano-HA/rhBMP-2 composite artificial bone and Nano-HA artificial bone could stimulate new bone formation, but the former could stimulate more new bone formation and had better repairing ability for bone defect than that of the latter, with statistically significant difference (P <0.05).
  
  
  CONCLUSIONS
  Nano-HA/rhBMP-2 composite artificial bone has good repairing ability for bone defect and it is hopeful to become an ideal repairing material for bone defect.
authors.affiliation: Department of Sports Medicine, Shenzhen Second People's Hospital, Shenzhen, China.
authors.forename: Weimin
authors.initials: W
authors.lastname: Zhu
authors.forename: Daping
authors.initials: D
authors.lastname: Wang
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Lu
authors.forename: Yun
authors.initials: Y
authors.lastname: Han
authors.forename: Yangkan
authors.initials: Y
authors.lastname: Ou
authors.forename: Ke
authors.initials: K
authors.lastname: Zhou
authors.forename: Wenzhe
authors.initials: W
authors.lastname: Fen
authors.forename: Jianquan
authors.initials: J
authors.lastname: Liu
authors.forename: Liangquan
authors.initials: L
authors.lastname: Peng
authors.forename: Chunlei
authors.initials: C
authors.lastname: He
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Zeng
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000627:therapeutic use; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D018786:Bone Substitutes / Q000737:chemistry / Q000378:metabolism; D017886:Durapatite / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D053758:Nanoparticles; D011817:Rabbits; D011859:Radiography; D011877:Radionuclide Imaging; D011884:Radius / Q000000981:diagnostic imaging / Q000502:physiology / Q000601:surgery; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000627:therapeutic use*; D023822:Tissue Engineering / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000627:therapeutic use*; D014965:X-Rays
chemical_list: D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D017886:Durapatite